These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2988 related articles for article (PubMed ID: 32278004)

  • 1. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
    Eslam M; Newsome PN; Sarin SK; Anstee QM; Targher G; Romero-Gomez M; Zelber-Sagi S; Wai-Sun Wong V; Dufour JF; Schattenberg JM; Kawaguchi T; Arrese M; Valenti L; Shiha G; Tiribelli C; Yki-Järvinen H; Fan JG; Grønbæk H; Yilmaz Y; Cortez-Pinto H; Oliveira CP; Bedossa P; Adams LA; Zheng MH; Fouad Y; Chan WK; Mendez-Sanchez N; Ahn SH; Castera L; Bugianesi E; Ratziu V; George J
    J Hepatol; 2020 Jul; 73(1):202-209. PubMed ID: 32278004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty liver disease - non alcoholic to metabolic - A transition of concepts!!
    Bawiskar N; Acharya S; Kumar S
    J Family Med Prim Care; 2024 Aug; 13(8):2857-2862. PubMed ID: 39228650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease.
    Fouad Y; Alboraie M; Shiha G
    Hepatol Int; 2024 Oct; 18(Suppl 2):827-833. PubMed ID: 38967907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
    Méndez-Sánchez N; Díaz-Orozco LE
    Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why MASLD Lags Behind MAFLD: A Critical Analysis of Diagnostic Criteria Evolution in Metabolic Dysfunction-Associated Liver Diseases.
    Alboraie M; Butt AS; Piscoya A; Dao Viet H; Hotayt B; Al Awadhi S; Bahcecioglu IH; Alkhalidi N; Al Mahtab M; Méndez-Sánchez N
    Med Sci Monit; 2024 Jul; 30():e945198. PubMed ID: 39075772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
    Eslam M; Alkhouri N; Vajro P; Baumann U; Weiss R; Socha P; Marcus C; Lee WS; Kelly D; Porta G; El-Guindi MA; Alisi A; Mann JP; Mouane N; Baur LA; Dhawan A; George J
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):864-873. PubMed ID: 34364544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
    Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
    Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
    Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Oct; 18(Suppl 2):834-847. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
    Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact.
    Alisi A; McCaughan G; Grønbæk H
    Hepatol Int; 2024 Oct; 18(Suppl 2):861-872. PubMed ID: 38995341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of metabolic dysfunction-associated fatty liver disease with kidney disease.
    Wang TY; Wang RF; Bu ZY; Targher G; Byrne CD; Sun DQ; Zheng MH
    Nat Rev Nephrol; 2022 Apr; 18(4):259-268. PubMed ID: 35013596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAFLD: How is it different from NAFLD?
    Gofton C; Upendran Y; Zheng MH; George J
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S17-S31. PubMed ID: 36443926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
    Zhou XD; Targher G; Byrne CD; Somers V; Kim SU; Chahal CAA; Wong VW; Cai J; Shapiro MD; Eslam M; Steg PG; Sung KC; Misra A; Li JJ; Brotons C; Huang Y; Papatheodoridis GV; Sun A; Yilmaz Y; Chan WK; Huang H; Méndez-Sánchez N; Alqahtani SA; Cortez-Pinto H; Lip GYH; de Knegt RJ; Ocama P; Romero-Gomez M; Fudim M; Sebastiani G; Son JW; Ryan JD; Ikonomidis I; Treeprasertsuk S; Pastori D; Lupsor-Platon M; Tilg H; Ghazinyan H; Boursier J; Hamaguchi M; Nguyen MH; Fan JG; Goh GB; Al Mahtab M; Hamid S; Perera N; George J; Zheng MH
    Hepatol Int; 2023 Aug; 17(4):773-791. PubMed ID: 37204656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
    Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    Nan Y; An J; Bao J; Chen H; Chen Y; Ding H; Dou X; Duan Z; Fan J; Gao Y; Han T; Han Y; Hu P; Huang Y; Huang Y; Jia J; Jiang J; Jiang Y; Li J; Li J; Li R; Li S; Li W; Li Y; Lin S; Liu J; Liu S; Lu L; Lu Q; Luo X; Ma X; Rao H; Ren H; Ren W; Shang J; Shi L; Su M; Wang B; Wang R; Wei L; Wen Z; Wu B; Wu J; Xin S; Xing H; Xu J; Yan M; Yang J; Yang J; Yang L; Yang Y; Yu Y; Zhang L; Zhang L; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhao S; Zheng H; Zhou Y; Zhou Y; Zhuang H; Zuo W; Xu X; Qiao L
    J Hepatol; 2021 Aug; 75(2):454-461. PubMed ID: 34019941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
    Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 150.